Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models, Peer-Reviewed Study Shows
TELO sits 34% above its 52-week low of $0.888 on light trading volume (0.1× avg).
Summary
Telomir published peer-reviewed preclinical data in the Journal of Oncology Research and Therapy showing Telomir-Zn suppresses tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models. The study provides direct proof of an iron-dependent mechanism via iron-rescue experiments, demonstrating the compound kills cancer cells by depleting intracellular iron required for KDM enzyme activity. Key findings include selective killing of cancer cells over normal cells, reactivation of silenced tumor-suppressor genes, and anti-metastatic activity in TNBC xenografts. Combination with paclitaxel enhanced tumor reduction, while non-response in one cell line suggests future patient stratification potential. This publication follows earlier preclinical data releases and supports the planned Phase 1/2 trial in TNBC, adding mechanistic depth that strengthens the scientific rationale for clinical development.
At the time of this announcement, TELO was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $0.89 to $2.09. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.